The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib

References

• Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82
   PubMed Web of Science ®Google Scholar
• Mani S. UGT1A1 polymorphism predicts irinotecan toxicity: evolving proof. AAPS PharmSci 2001;3:2
   PubMedGoogle Scholar
• Tan BR, McLeod HL. Pharmacogenetic influences on treatment response and toxicity in colorectal cancer. Semin Oncol 2005;32:113-9
   PubMed Web of Science ®Google Scholar
• Krynetski EY, Evans WE. Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S-methyltransferase paradigm. Pharm Res 1999;16:342-9
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Cancer Facts & Figures 2016. Atlanta: American Cancer Society; 2016
   Google Scholar
• Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6
   PubMed Web of Science ®Google Scholar
• Shaw AT, Solomon BJ. Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer. The Netherlands: Wolters Kluwer; Alphen aan den Rijn 2016. http://www.uptodate.com/contents/anaplastic-lymphoma-kinase-alk-fusion-oncogene-positive-non-small-cell-lung-cancer. Accessed March 27, 2016
   Google Scholar
• XALKORI® (crizotinib) capsules, for oral use. New York: Pfizer, Inc; 2016. http://labeling.pfizer.com/showlabeling.aspx?id = 676. Accessed March 1, 2016
   Google Scholar
• Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012;18:1472-82
   PubMed Web of Science ®Google Scholar
• Katayama R, Friboulet L, Koike S, et al. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Clin Cancer Res 2014;20:5686-96
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014;371:2167-77
   PubMed Web of Science ®Google Scholar
• Ou S-HI, Ahn JS, De Petris L, et al. Efficacy and safety of the ALK inhibitor alectinib in ALK + non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: an open-label, single-arm, global phase 2 study (NP28673). Paper presented at the ASCO Annual Meeting Proceedings; Chicago, June 2-6 2015
   Google Scholar
• Shaw AT, Gandhi L, Gadgeel S, et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol 2015;17:234?42
   PubMed Web of Science ®Google Scholar
• Mok T, Spigel D, Felip E, et al. ASCEND-2: A single-arm, open-label, multicenter phase 2 study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung vancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ). Paper presented at the American Society of Clinical Oncology (ASCO); June 2015; Chicago, IL.
   Google Scholar
• Felip E, Kim DW, Mehra R. Efficacy and safety of ceritinib in patients with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): an update of ASCEND-1. Paper presented at the European Society of Medical Oncology (ESMO); 26 Sep - 30 Sep 2014; Madrid, Spain
   Google Scholar
• Kim DW, Mehra R, Tan DS, et al. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol 2016;17:452?63
   PubMed Web of Science ®Google Scholar
• Ou SI, Ahn JS, De Petris L, et al. Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study. J Clin Oncol 2015;34:661-68
   PubMed Web of Science ®Google Scholar
• Barlesi F, Dingemans A-MC, Ou S-HI. Updated efficacy and safety results from a global phase II, open-label, single-arm study (NP28673) of alectinib in crizotinib-refractory ALK + non-small-cell lung cancer (NSCLC). Paper presented at the European Society of Medical Oncology; 25 Sep - 29 Sep 2015
   Google Scholar
• Gadgeel S, Shaw A, Govindan R, et al. Pooled analysis of CNS response to alectinib in two studies of pre-treated ALK + NSCLC. Paper presented at WCLC; Sept 6-9 2015; Denver, Colorado
   Google Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology non-small cell lung cancer. Fort Washington: NCCN, Inc.; 2016
   Google Scholar
• Shaw AT, West H, Socinski MA. Updated efficacy/safety data from the phase II NP28761 study of alectinib in ALK + NSCLC. World Conference on Lung Cancer (WCLC); Sept. 6-9 2015; Denver, CO
   Google Scholar
• Felip E, Kim D-W, Mehra R, et al. Efficacy and safety of ceritinib in patients with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): An update of ASCEND-1. Paper presented at the European Society of Medical Oncology (ESMO); September 2014; Madrid, Spain
   Google Scholar
• Genentech. Data on File. 2015
   Google Scholar
• Hoyle MW, Henley W. Improved curve fits to summary survival data: application to economic evaluation of health technologies. BMC Med Res Method 2011;11:139
   PubMed Web of Science ®Google Scholar
• Novartis Pharmaceuticals Corporation. ZYKADIA™ highlights of prescribing information. Basel, Switzerland: Novartis Pharmaceuticals Corporation 2015
   Google Scholar
• First DataBank, Inc. Analy$ource Online: the online resource for drug pricing and deal information. South San Francisco, CA: First DataBank, Inc. 2016
   Google Scholar
• Center for Medicare and Medicaid Services. Acute inpatient prospective payment system. Baltimore, MD; 2015; http://www.cms.hhs.gov/AcuteInpatientPPS. Accessed March 1, 2016
   Google Scholar
• Centers for Medicare & Medicaid Services. Physician fee schedule national payment amount. Centers for Medicare & Medicaid Services; 2015
   Google Scholar
• Amgen Inc. EPOGEN® (Epoetin alfa) FOR INJECTION. Thousand Oaks, CA; 2016
   Google Scholar
• The Scottish Medicines Consortium. Ceritinib 150 mg hard capsules (Zykadia®) SMC No. (1097/15). Glasgow, Scotland: The Scottish Medicines Consortium 2015. https://www.scottishmedicines.org.uk/files/advice/ceritinib__Zykadia__FINAL_Nov_2015_for_website.pdf. Accessed December 20, 2015
   Google Scholar
• Zhou ZY, Zhang J, Morga A, et al. Cost-effectiveness of ceritinib in the treatment of previously treated anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer in the United Kingdom. Paper presented at the ISPOR 18th Annual European Meeting; November 2015; Milan, Italy
   Google Scholar
• Nafees B, Stafford M, Gavriel S, et al. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes 2008;6:84
   PubMed Web of Science ®Google Scholar
• First DataBank, Inc. Analy source Online: the online resource for drug pricing and deal information. South San Francisco, CA: 2016
   Google Scholar
• Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 2011;103:117-28
   PubMed Web of Science ®Google Scholar
• Briggs AH, Claxton K, Sculpher MJ. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006
   Google Scholar
• Riley W, Smalley B, Pulkrabek S, et al. Using lean techniques to define the platelet (PLT) transfusion process and cost-effectiveness to evaluate PLT dose transfusion strategies. Transfusion 2012;52:1957-67
   PubMed Web of Science ®Google Scholar
• Center for Medicare and Medicaid Services. Physician fee schedule and acute inpatient prospective payment system. Baltimore, MD: Center for Medicare and Medicaid Services 2007. http://www.cms.hhs.gov/PhysicianFeeSched/PFSFRN/list.asp and http://www.cms.hhs.gov/AcuteInpatientPPS. Accessed May 5, 2007
   Google Scholar
• Costa DB, Shaw AT, Ou SH, et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol 2015;33:1881-8
   PubMed Web of Science ®Google Scholar
• Shi W, Dicker AP. CNS metastases in patients with non-small-cell lung cancer and ALK gene rearrangement. J Clin Oncol 2016;34:107-9
   PubMed Web of Science ®Google Scholar
• Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov 2014;4:662-73
   PubMed Web of Science ®Google Scholar
• Genentech. ALECENSA® (alectinib) highlights of prescribing information. South San Francisco, CA: Genentech 2016
   Google Scholar
• ClinicalTrials.gov. Bethesda, MD: 2016. https://clinicaltrials.gov/. Accessed March 7, 2016
   Google Scholar
• Hiroshi Nokihara TH, Masashi K, Young HK, et al. Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK + NSCLC): Primary results from the J-ALEX study. Paper presented at the 2016 ASCO Annual Meeting; 2016; Chicago, IL
   Google Scholar
• Zhou Z, Zhang J, Morga A, et al. Cost-effectiveness of ceritinib in the treatment of previously treated anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer in the United Kingdom. Paper presented at the ISPOR 18th Annual European Meeting; 2015; Milan, Italy
   Google Scholar
• Hurry M, Zhou ZY, Zhang J, et al. Cost-effectiveness of ceritinib in patients previously treated with crizotinib in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer in Canada. J Med Econ 2016;19:936-44
   PubMed Web of Science ®Google Scholar